Origin Biopharma supplies high-quality Toceranib Veterinary API developed for veterinary oncology cancer formulations, particularly for companion animal therapies. Our material supports veterinary drug developers, formulation scientists, and CDMOs seeking reliable, GMP-grade APIs for both development and commercial manufacturing.

Beyond basic product listing, we focus on practical integration into your workflow-offering evaluation samples, scalable bulk supply, and regulatory documentation to reduce development risk and timelines.

Product Overview

Toceranib (CAS 356068-94-5) is a multi-target tyrosine kinase inhibitor primarily used in the treatment of canine mast cell tumors. It selectively inhibits c-Kit, VEGFR, and PDGFR, making it a critical API for veterinary oncology drug development.

This API is suitable for:

▸ Veterinary pharmaceutical companies developing oncology therapies

▸ Contract development and manufacturing organizations (CDMOs)

▸ Animal health companies preparing products for regulatory registration

Toceranib API can be formulated into oral solid dosage forms or other veterinary pharmaceutical preparations.

Main Applications in Veterinary Medicine

▸ Veterinary oncology targeting mast cell tumors in dogs

▸ Companion animal oral dosage forms and advanced formulations

▸ Animal health R&D requiring high-purity oncology APIs

Specifications & Quality Details

▸ CAS Number: 356068-94-5

▸ Molecular Formula: C₂₂H₂₅FN₄O₂

▸ Molecular Weight: ~396.46 g/mol

▸ Appearance: White to off-white crystalline powder

▸ Purity: ≥ 98% (HPLC)

▸ Solubility: Soluble in DMSO; limited in water

▸ Manufacturing: GMP-compliant

▸ Documentation: COA, MSDS, TDS available

Packaging & Supply Options

▸ Standard: 1 kg foil bags, 25 kg fiber drums

▸ Custom packaging available

▸ Sample sizes: 100 g / 500 g

▸ Lead times & MOQ customized